A combination of hybrid-capture based next generation sequencing/ fluorescence in situ hybridization (n = 78) and whole exome sequencing/targeted TERT promoter sequencing (The Cancer Genome Atlas, n = 91) was used to define both the prevalence of copy number alterations and “hotspot” promoter mutations affecting the TERT gene in adrenocortical carcinomas. This evidence concerns the gene TERT and adrenal cortex carcinoma.